574-25-4Relevant articles and documents
Huang et al.
, p. 1363,1364,1366 (1975)
Heterocyclic compound containing SCF3 or SeCF3, and preparation method thereof
-
Paragraph 0097-0100, (2020/07/12)
The invention discloses a heterocyclic compound containing SCF3 or SeCF3, and a preparation method thereof. The preparation method comprises: dissolving a chlorinated heterocyclic compound 1 in an EtOH solution, adding 1.0-2.0 equivalent weight of thiourea or selenourea, then stirring for 1-8 hours at 50-120 DEG C, and reacting to obtain a compound 2; and dissolving the compound 2 in an Acetone orEA solution, adding 2.0-4.0 equivalent weight of CF3SO2Na and 0.2-0.4 equivalent weight of a Cu salt, adding 2.0-4.0 equivalent weight of a tBuOOH solution in a dropwise manner, and reacting at 25-40DEG C for 1.0-2.0 hours to obtain a compound 3, namely the required SCF3 or SeCF3-containing heterocyclic compound. According to the invention, the synthesized compound has huge potential in the aspect of treating diseases; and according to the synthetic route provided by the invention, amplification can be realized in each step, the yield can reach 85%, the synthetic route provided by the invention brings a simpler and more effective way for synthesis of compounds with biological activity, the yield is high, large-scale preparation can be realized, and the synthetic route has a very wide application prospect.
Chemoselective Perfluoromethylation of Thio- And Selenoamides
Xu, Tao,Xu, Xianhong,Zhang, Jianyu
supporting information, (2020/11/13)
A chemo- and regioselective perfluoromethylation using thioamides/selenoamides (prepared one step from corresponding lactams) as starting materials has been discovered. The reaction demonstrated complementary chemoselectivity to the C-H trifluoromethylation of (hetero)arenes as well as remarkable functional group compatibility especially toward radical sensitive olefin-, alkyne-, and arylhalide-bearing substrates. The examples of perfluorothio-/selenolated drug molecules indicated application potential of this strategy in drug modification and drug-analogue preparation.
α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors
Bhattarai, Sanjay,Freundlieb, Marianne,Pippel, Jan,Meyer, Anne,Abdelrahman, Aliaa,Fiene, Amelie,Lee, Sang-Yong,Zimmermann, Herbert,Yegutkin, Gennady G.,Str?ter, Norbert,El-Tayeb, Ali,Müller, Christa E.
supporting information, p. 6248 - 6263 (2015/08/24)
ecto-5′-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics. The eN inhibitor α,β-methylene-ADP (AOPCP, adenosine-5′-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared. Products were tested at rat recombinant eN. 6-(Ar)alkylamino substitution led to the largest improvement in potency. N6-Monosubstitution was superior to symmetrical N6,N6-disubstitution. The most potent inhibitors were N6-(4-chlorobenzyl)- (10l, PSB-12441, Ki 7.23 nM), N6-phenylethyl- (10h, PSB-12425, Ki 8.04 nM), and N6-benzyl-adenosine-5′-O-[(phosphonomethyl)phosphonic acid] (10g, PSB-12379, Ki 9.03 nM). Replacement of the 6-NH group in 10g by O (10q, PSB-12431) or S (10r, PSB-12553) yielded equally potent inhibitors (10q, 9.20 nM; 10r, 9.50 nM). Selected compounds investigated at the human enzyme did not show species differences; they displayed high selectivity versus other ecto-nucleotidases and ADP-activated P2Y receptors. Moreover, high metabolic stability was observed. These compounds represent the most potent eN inhibitors described to date.
